Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ: NTRA )

173.39 +2.66 (+1.56%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma
From Natera, Inc.
Via Business Wire
Natera Announces National Commercial Coverage for its Fetal RhD NIPT
From Natera, Inc.
Via Business Wire
Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer
From Natera, Inc.
Via Business Wire
Natera to Present New Data at the 2025 ASCO GI Symposium
From Natera, Inc.
Via Business Wire
Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year
From Natera, Inc.
Via Business Wire
Natera Announces Innovation Roadmap, with Advancements in MRD and Early Cancer Detection
From Natera, Inc.
Via Business Wire
Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024
From Natera, Inc.
Via Business Wire
Natera to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Natera, Inc.
Via Business Wire
Court Grants Natera’s Request to Include Additional Patent in its Lawsuit Against NeoGenomics
From Natera, Inc.
Via Business Wire
Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer
From Natera, Inc.
Via Business Wire
Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment
From Natera, Inc.
Via Business Wire
Clinical Validation Study on Natera’s Fetal RhD NIPT Published in Obstetrics & Gynecology
From Natera, Inc.
Via Business Wire
Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients
From Natera, Inc.
Via Business Wire
Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium
From Natera, Inc.
Via Business Wire
Natera Issues Statement on Guardant Health Litigation
From Natera, Inc.
Via Business Wire
Natera Co-Founder and Executive Chairman Matthew Rabinowitz Named 2024 R&D Leader of the Year
From Natera, Inc.
Via Business Wire
Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM
From Natera, Inc.
Via Business Wire
Natera Reports Third Quarter 2024 Financial Results
From Natera, Inc.
Via Business Wire
Natera Announces Completion of Signatera™ Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer
From Natera, Inc.
Via Business Wire
Natera to Participate in Upcoming Investor Conferences
From Natera, Inc.
Via Business Wire
Natera to Report its Third Quarter 2024 Results on November 12, 2024
From Natera, Inc.
Via Business Wire
Natera to Present New Renasight Data at ASN Kidney Week 2024
From Natera, Inc.
Via Business Wire
Court Orders Permanent Injunction Against NeoGenomics' Accused RaDaR Assay, as Case Enters New Phase
From Natera, Inc.
Via Business Wire
Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMO
From Natera, Inc.
Via Business Wire
First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival
From Natera, Inc.
Via Business Wire
Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival
From Natera, Inc.
Via Business Wire
Natera Reports Second Quarter 2024 Financial Results
From Natera, Inc.
Via Business Wire
Natera to Participate in the Canaccord Genuity 44th Annual Growth Conference
From Natera, Inc.
Via Business Wire
Natera to Report its Second Quarter 2024 Results on August 8, 2024
From Natera, Inc.
Via Business Wire
New MultiCenter Prospective Study Demonstrates Signatera’s Clinical Utility in Merkel Cell Carcinoma
From Natera, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.